Pfizer, Inc. (NYSE:PFE) was the target of some unusual options trading activity on Monday. Traders bought 24,211 call options on the stock. This represents an increase of 129% compared to the typical daily volume of 10,577 call options.

A number of brokerages recently issued reports on PFE. Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a report on Tuesday. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the stock a “buy” rating in a report on Tuesday, September 19th. Morgan Stanley upgraded shares of Pfizer from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $35.00 to $39.00 in a report on Wednesday, September 20th. Vetr cut shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price objective for the company. in a report on Wednesday, September 13th. Finally, Jefferies Group LLC set a $37.00 price objective on shares of Pfizer and gave the stock a “neutral” rating in a report on Monday, September 18th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. Pfizer currently has an average rating of “Hold” and a consensus target price of $38.21.

Shares of Pfizer (NYSE:PFE) opened at 35.96 on Thursday. Pfizer has a 1-year low of $29.83 and a 1-year high of $36.24. The stock’s 50 day moving average is $34.55 and its 200 day moving average is $33.66. The company has a market capitalization of $213.87 billion, a PE ratio of 26.31 and a beta of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company had revenue of $12.90 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same period in the previous year, the firm posted $0.64 EPS. The firm’s revenue was down 1.9% on a year-over-year basis. On average, equities research analysts anticipate that Pfizer will post $2.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.56%. The ex-dividend date of this dividend is Thursday, November 9th. Pfizer’s payout ratio is 94.12%.

In other news, CEO Ian C. Read sold 96,950 shares of the business’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Sally Susman sold 38,230 shares of the business’s stock in a transaction on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PFE. Asset Planning Services Ltd. grew its holdings in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. grew its holdings in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Finally, Herndon Capital Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $120,000. 69.00% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/10/05/stock-traders-buy-high-volume-of-pfizer-call-options-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.